RI may also be influenced by reimbursement and pricing decisions, the impact of competitive products, the pace of market acceptance, and any material issues, delays or failures related to its manufacturing and supply. For more detailed information on the risks and uncertainties associated with TYSABRI and the companies' drug development and other activities, see the periodic and other reports of Biogen Idec Inc. and Elan Corporation, plc filed with the Securities and Exchange Commission. The companies assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

'"/>

Contact: Amy Losak
646-935-9317
Ketchum
23-Nov-2004

Page: 1 2 3 4 5 6
Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. US FDA grants full approval to DOXIL(R) following submission of phase III data
4. Four teams awarded inaugural translational cancer research grants
5. Immigrants, beware: Living in the United States is fattening
6. Prevalence of obesity among immigrants increases with longer residency in US
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research